Tolterodine - PMC

Martina S. Burczyk, Martin D. Burkhalter, Teresa Casar Tena, Laurel A. Grisanti, Michael Kauk, Sabrina Matysik, Cornelia Donow, Monika Kustermann, Melanie Rothe, Yinghong Cui, Farah Raad, Svenja Laue, Allessandra Moretti, Wolfram-H. Zimmermann, Jürgen Wess, Michael Kühl, Carsten Hoffmann, Douglas G. Tilley, Melanie Philipp

JCI Insight. 2019 Oct 17; 4(20): e121971. Published online 2019 Oct 17. doi: 10.1172/jci.insight.121971

PMCID:: PMC6824298

Article PDF–8.1M

Select item 32933618.

A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples

Ramesh Yanamandra, Chandra Sekhar Vadla, Umamaheshwar Puppala, Balaram Patro, Yellajyosula. L. N. Murthy, Parimi Atchuta Ramaiah

Sci Pharm. 2012 Jan-Mar; 80(1): 101–114. Published online 2011 Dec 5. doi: 10.3797/scipharm.1110-14

PMCID:: PMC3293361

Article PDF–245K

Select item 55574489.

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function

Athanasios Zachariou, Maria Filiponi

Int Braz J Urol. 2017 Jul-Aug; 43(4): 713–720. doi: 10.1590/S1677-5538.IBJU.2016.0303

PMCID:: PMC5557448

Article PDF–141K

Select item 1056895910.

Formulation and evaluation of taste-masked oral disintegrating tablet containing tolterodine-loaded montmorillonite

Somayeh Taymouri, Abolfazl Mostafavi, Homa Talabaki

Res Pharm Sci. 2023 Sep-Oct; 18(5): 528–540. Published online 2023 Aug 20. doi: 10.4103/1735-5362.383708

PMCID:: PMC10568959

Article PDF–934K

Select item 423034611.

Tolterodine extended release in the treatment of male oab/storage luts: a systematic review

Mauro Gacci, Giacomo Novara, Cosimo De Nunzio, Andrea Tubaro, Riccardo Schiavina, Eugenio Brunocilla, Arcangelo Sebastianelli, Matteo Salvi, Matthias Oelke, Stavros Gravas, Marco Carini, Sergio Serni

BMC Urol. 2014; 14: 84. Published online 2014 Oct 27. doi: 10.1186/1471-2490-14-84

PMCID:: PMC4230346

Article PDF–934K

Select item 646915812.

On the Absolute Stereochemistry of Tolterodine: A Circular Dichroism Study

Marcin Górecki, Valerio Zullo, Anna Iuliano, Gennaro Pescitelli

Pharmaceuticals (Basel) 2019 Mar; 12(1): 21. Published online 2019 Jan 26. doi: 10.3390/ph12010021

PMCID:: PMC6469158

Article PDF–2.0M

Select item 400266913.

Combination of Foot Stimulation and Tolterodine Treatment Eliminates Bladder Overactivity in Cats

Zeyad Schwen, Yosuke Matsuta, Bing Shen, Jicheng Wang, James R. Roppolo, William C. de Groat, Changfeng Tai

Neurourol Urodyn. Author manuscript; available in PMC 2015 Nov 1.

Published in final edited form as: Neurourol Urodyn. 2014 Nov; 33(8): 1266–1271. Published online 2013 Aug 29. doi: 10.1002/nau.22479

PMCID:: PMC4002669

Article PDF–224K

Select item 578054014.

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

David Staskin, Sender Herschorn, Jonathan Fialkov, Le Mai Tu, Terry Walsh, Carol R. Schermer

Int Urogynecol J. 2018; 29(2): 273–283. Published online 2017 Jun 15. doi: 10.1007/s00192-017-3377-5

PMCID:: PMC5780540

Article PDF–1.5M

Select item 590921415.

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Sender Herschorn, David Staskin, Le Mai Tu, Jonathan Fialkov, Terry Walsh, Katherine Gooch, Carol R. Schermer

Health Qual Life Outcomes. 2018; 16: 69. Published online 2018 Apr 19. doi: 10.1186/s12955-018-0892-0

PMCID:: PMC5909214

Article PDF–1.3M

Select item 188450316.

Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers

Teng C Hua, Alan Pan, Clark Chan, Yeo K Poo, Michael H Skinner, Mary P Knadler, Celedon R Gonzales, Stephen D Wise

Br J Clin Pharmacol. 2004 May; 57(5): 652–656. doi: 10.1111/j.1365-2125.2004.02068.x

PMCID:: PMC1884503

Article PDF–107K

Select item 268524017.

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly

Danny Ulahannan, Adrian Wagg

Clin Interv Aging. 2009; 4(): 191–196. Published online 2009 May 14. doi: 10.2147/cia.s4233

PMCID:: PMC2685240

Article PDF–77K

Select item 491927918.

Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms after Randomized Single-Therapy Treatment

David Rich Ellington, Jeffery Michael Szychowski, Joseph Michael Malek, Kimberly Anne Gerten, Kathryn Larsen Burgio, Holly Elizabeth Richter

Female Pelvic Med Reconstr Surg. Author manuscript; available in PMC 2017 Jul 1.

Published in final edited form as: Female Pelvic Med Reconstr Surg. 2016 Jul-Aug; 22(4): 254–260. doi: 10.1097/SPV.0000000000000256

PMCID:: PMC4919279

Article PDF–408K

Select item 426524119.

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

S A Kaplan, L Cardozo, S Herschorn, L Grenabo, M Carlsson, D Arumi, T J Crook, L Whelan, D Scholfield, F Ntanios

Int J Clin Pract. 2014 Sep; 68(9): 1065–1073. Published online 2014 Jun 4. doi: 10.1111/ijcp.12464

PMCID:: PMC4265241

Article PDF–225K

Select item 316265220.

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers

Bimal Malhotra, Edress Darsey, Penelope Crownover, Juanzhi Fang, Paul Glue

Br J Clin Pharmacol. 2011 Aug; 72(2): 226–234. doi: 10.1111/j.1365-2125.2011.03948.x

PMCID:: PMC3162652

Article PDF–1.2M

<< First< Prev

Page of 112

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for Tolterodine

Fig. 1

HR-MS and MS–MS data of tolterodine and the unknown impurity (a) HR-MS spectra of tolterodine, (b) MS–MS spectra of tolterodine, (c) HR-MS spectra of the impurity, (d) MS–MS spectra of the impurity

Isolation, Identification, and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in the Tolterodine Tartrate Formulation

Sci Pharm. 2015 Jan-Mar;83(1):65-83.
Fig. 6

Mean plasma concentrations versus time graph of tolterodine and 5-hydroxy methyl tolterodine after intravenous administration of 0.072 mg/200 g tolterodine in male rats.

A validated LC–MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study

J Pharm Anal. 2013 Dec;3(6):489-499.
Fig. 1

Chemical structures of tolterodine, tolterodine-d6, 5-hydroxy methyl tolterodine, and 5-hydroxy methyl tolterodine-d14.

A validated LC–MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study

J Pharm Anal. 2013 Dec;3(6):489-499.
Fig. 5

Chromatogram of tolterodine, tolterodine-d6 and 5-hydroxy methyl tolterodine, 5-hydroxy methyl tolterodine-d14 at LOQ level.

A validated LC–MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study

J Pharm Anal. 2013 Dec;3(6):489-499.

See more (211)...

Find related data

Search details

Recent activity

Clear Turn Off Turn On

Tolterodine (2222)
PMC

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

You are here: NCBI > Literature > PubMed Central (PMC)

Support Center

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

PMC Full-Text Search Results

Items: 1 to 20 of 2222